Antibiotic after sex significantly reduces cases of syphilis and chlamydia
New cases have fallen by half in just over a year, San Francisco health officials reported.
< p class="css-at9mc1 evys1bk0"> A single dose of the widely used antibiotic doxycycline, taken after sexual intercourse, halved the incidence of chlamydia and early syphilis in gay and bisexual men and women. transgender women in San Francisco, city health officials announced Monday. The findings offer a glimmer of hope amid a growing wave of sexually transmitted infections nationwide.The strategy is called doxy-PEP, short for post-exposure prophylaxis with doxycycline. In San Francisco, gay and bisexual men and transgender women with a history of STIs or with multiple sexual partners were given an antibiotic and told to take two 100-milligram tablets within 72 hours of unprotected sex.
New cases of chlamydia and early syphilis – but not gonorrhea – have declined in about a year. The results were presented at the Conference on Retroviruses and Opportunistic Infections in Denver.
“It's not subtle, it's very rapid and we let’s see the beginning, not the end,” Dr. Hyman Scott, medical director of the San Francisco Department of Public Health, said in an interview. “This is what we want for S.T.I. prevention. »
Strategies to contain STIs are absolutely necessary.
Syphilis, once almost eliminated in the United States United States, reached the highest rate of new infections recorded since 1950, the Centers for Disease Control and Prevention reported in January. If left untreated, syphilis can damage the heart and brain and cause blindness, deafness and paralysis.
Chlamydia rates have remained stable nationwide in 2022, compared to 2021, but with nearly 1.7 million cases, infections were common. (Gonorrhea cases declined in 2022, but experts have warned that this trend could be the result of less testing.)
We are struggling to recover the content of the article.
We are having trouble retrieving the content of the article.
Please enable JavaScript in your browser settings.
Thank you for your patience while we verify access. If you are in Reader mode, please exit and log in to your Times account, or subscribe to the entire Times.
New cases have fallen by half in just over a year, San Francisco health officials reported.
< p class="css-at9mc1 evys1bk0"> A single dose of the widely used antibiotic doxycycline, taken after sexual intercourse, halved the incidence of chlamydia and early syphilis in gay and bisexual men and women. transgender women in San Francisco, city health officials announced Monday. The findings offer a glimmer of hope amid a growing wave of sexually transmitted infections nationwide.The strategy is called doxy-PEP, short for post-exposure prophylaxis with doxycycline. In San Francisco, gay and bisexual men and transgender women with a history of STIs or with multiple sexual partners were given an antibiotic and told to take two 100-milligram tablets within 72 hours of unprotected sex.
New cases of chlamydia and early syphilis – but not gonorrhea – have declined in about a year. The results were presented at the Conference on Retroviruses and Opportunistic Infections in Denver.
“It's not subtle, it's very rapid and we let’s see the beginning, not the end,” Dr. Hyman Scott, medical director of the San Francisco Department of Public Health, said in an interview. “This is what we want for S.T.I. prevention. »
Strategies to contain STIs are absolutely necessary.
Syphilis, once almost eliminated in the United States United States, reached the highest rate of new infections recorded since 1950, the Centers for Disease Control and Prevention reported in January. If left untreated, syphilis can damage the heart and brain and cause blindness, deafness and paralysis.
Chlamydia rates have remained stable nationwide in 2022, compared to 2021, but with nearly 1.7 million cases, infections were common. (Gonorrhea cases declined in 2022, but experts have warned that this trend could be the result of less testing.)
We are struggling to recover the content of the article.
We are having trouble retrieving the content of the article.
Please enable JavaScript in your browser settings.
Thank you for your patience while we verify access. If you are in Reader mode, please exit and log in to your Times account, or subscribe to the entire Times.
What's Your Reaction?
